Market Research Reports and Industry Reports

Market Access Impact (US) [NSCLC]

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS



Eliminating market barriers could help lower-ranked brands a narrow lead

Three brands are way ahead in the US non-small cell lung cancer (NSCLC) market, thanks in part to market barriers that prevent oncologists from prescribing competing treatments. Eliminating these barriers wont be enough for lower-ranked brands to catch up to the market leaders, but it could give a few of them the market share bump they need to overtake their closest rivals.

Get the details in Market Access Impact: NSCLC (US).

Youll see how widely prescribed your brand is, and learn how 7 barriers affect your market share. Youll also find out how much share you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 100 US-based medical oncologists and primary care physicians, the report covers 13 major therapies from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck & Co., Novartis, Pfizer/Merck Group, and Roche

Not your market? Click here to see the EU5 report

Request sample pages





Top Takeaways

Barriers affect nearly 20% of prescriptions: High cost is the biggest issue, but each of the 6 other surveyed barriers affects roughly the same number of prescriptions.
Three brands dominate: Their respective market shares are at most 4% apart. However, significantly more doctors prescribe the top two brands than the third-place runner-up.
A battle of inches: Barriers only have a modest effect on market share, but its enough to hold at least two brands back. Eliminating barriers would push each of them up by one spot.
Problem areas: Some barriers have an outsized effect on some brands, e.g., high cost is the issue for one leading brand, while two lower-ranked rivals, have big reimbursement problems.
Barrier effect is widespread: At least 50% of doctors experience one or more barriers with every surveyed brand.
Overall perception is good: Most doctors either prescribe, or would consider prescribing all of the surveyed brands, and no more than 5% of doctors are unaware of any given brand.

Insight into 13 Major NSCLC Drugs

Avastin (bevacizumab; Roche)
Alecensa (alectinib; Roche)
Cyramza (ramucirumab; Eli Lilly)
Gilotrif (afatinib; Boehringer Ingelheim)
Iressa (gefitinib; AstraZeneca)
Keytruda (pembrolizumab; Merck & Co.)
Opdivo (nivolumab; Bristol-Myers Squibb)
Portrazza (necitumumab; Eli Lilly)
Tagrisso (osimertinib; AstraZeneca)
Tarceva (erlotinib; Roche)
Tecentriq (atezolizumab; Roche)
Xalkori (crizotinib; Pfizer/Merck Group)
Zykadia (ceritinib; Novartis)

Exploring Market Access Barriers

Market Access Impact: NSCLC (US) explores key issues affecting drug manufacturers. Youll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many dont, but would consider it?
Why dont doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?


A Report Based on Expert Knowledge

We surveyed 100 US-based medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

Have been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with NSCLC in total in the last month

We conducted the survey between August 1st and 16th, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If youre not completely satisfied, well refund your money. Guaranteed.

About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your companys success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.
1. What are market barriers?
2. About this report
3. About the survey
4. Brands included in the survey
5. Executive summary

Global Small Scale LNG (SSLNG) Market By Application (Industrial, Transportation, etc.), By Mode of Supply (Truck, Transshipment & Bunkering, etc.), By Region, By OEM Company, By Marketing Company, Competition Forecast & Opportunities, 2012 – 2026

Global small scale LNG (SSLNG) market stood at $ 25.7 billion in 2016, and the market is projected to reach $ 51.9 billion by 2026. Globally, growing demand for SSLNG

USD 4000View Report

UAE Interior Fit Out Market By Application (Offices, Hotels, Resort & Leisure, Retail, Healthcare, Education & Others), By Region (Dubai, Abu Dhabi, Sharjah & Other Emirates), Competition Forecast and Opportunities, 2022

UAE interior fit out market is forecast to reach $ 973.4 million by 2022. Anticipated growth in the market can be attributed to booming commercial sector and rising number of

USD 2500View Report

Key Success Factors in Pricing, Reimbursement and Market Access

Key Success Factors in Pricing, Reimbursement and Market AccessNovel pricing and reimbursement models are shaping the uptake of medicines. Yet the market access goalposts keep being moved as payer policies,

USD 695View Report

Market Access Impact (EU5) [NSCLC]

Eliminating prescription barriers could break the tie at the top of the marketThe two leading brands in the EU5 non-small cell lung cancer (NSCLC) market are tied for market share,

USD 5145View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 5145
  • Enterprise Wide Licence    USD 7725
$ 5145

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
pendik escort tuzla escort antalya escort bayan kartal escort
instagram takipci hilesi
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop